Publications by authors named "Giuseppe Guardascione"
Article Synopsis
- Circulating Tumor Cells (CTCs) are rare cancer cells that can lead to metastasis; a new gel (CLG) containing CXCL12 was created to attract and study these cells, particularly those expressing CXCR4 that facilitate invasion.
- Different cancer cell lines (colon, renal, lung, and ovarian) were tested on the gel, revealing that the CXCL12-loaded gel significantly enhanced the ability of CTCs to infiltrate compared to an empty gel.
- In a clinical trial, CTCs were successfully isolated from patients with ovarian and lung cancers using the CLG, showing promising results in identifying metastatic cells and understanding their behavior.
Article Synopsis
- The study aims to determine factors that predict sensitivity to nivolumab in patients with metastatic renal cell carcinoma (mRCC) by analyzing immune cell profiles, specifically peripheral blood NK cells and regulatory T-cells (Tregs).
- A total of 57 mRCC patients and 62 healthy donors were analyzed for various immune cell characteristics over the first year of treatment, using statistical methods to identify key predictors.
- Results indicated that KIR2DL2/DL3+ NK cells and Helios+ Tregs at pretreatment serve as important predictors of nivolumab response, with specific thresholds related to overall survival (OS) and progression-free survival (PFS) showing their potential significance in treatment outcomes.
Pancreatic ductal adenocarcinoma (PDAC) is currently the most deadly cancer. Although characterized by 5-20% of neoplastic cells in the highly fibrotic stroma, immunotherapy is not a valid option in PDAC treatment. As CXCR4-CXCL12 regulates tumor invasion and T-cell access and PD-1/PD-L1 controls immune tolerance, 76 PDACs were evaluated for CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in the epithelial and stromal component.
View Article and Find Full Text PDFBackground: Colorectal cancer (CRC) is one of the most prevalent and deadly tumors worldwide. The majority of CRC is resistant to anti-programmed cell death-1 (PD-1)-based cancer immunotherapy, with approximately 15% with high-microsatellite instability, high tumor mutation burden, and intratumoral lymphocytic infiltration. Programmed death-ligand 1 (PD-L1)/PD-1 signaling was described in solid tumor cells.
View Article and Find Full Text PDFThe chemokine receptor 4 (CXCR4) and 7 (CXCR7) are G-protein-coupled receptors (GPCRs) activated through their shared ligand CXCL12 in multiple human cancers. They play a key role in the tumor/tumor microenvironment (TME) promoting tumor progression, targeting cell proliferation and migration, while orchestrating the recruitment of immune and stromal cells within the TME. CXCL12 excludes T cells from TME through a concentration gradient that inhibits immunoactive cells access and promotes tumor vascularization.
View Article and Find Full Text PDF